Arvid Carlsson: The Chemical That Moves Us
In the late 1950s a Swedish pharmacologist gave rabbits a drug that stripped their brains of dopamine. The animals went rigid and stopped moving — an unmistakable model of Parkinson's disease. Then he gave them L-dopa, the chemical precursor the brain uses to build dopamine, and they got up and moved again. Arvid Carlsson had just demonstrated that a specific molecule in a specific part of the brain was responsible for movement, and that restoring it restored function. It remains one of the cleanest experiments in the history of neuroscience, and the treatment it produced is still the primary therapy for Parkinson's disease today.
Lund, 1941
Arvid Carlsson was born in Uppsala, Sweden, in 1923. The family moved to Lund when his father took a professorship in history, and Carlsson broke with his siblings by choosing medicine, entering Lund University in 1941. In 1944 he took part in the medical examination of prisoners rescued from Nazi concentration camps by Folke Bernadotte's mission — a formative encounter with the extremes of human physiology at the beginning of a career spent on its chemistry. He earned both his MD and his PhD in pharmacology by 1951.
The Neurotransmitter That Was Not Supposed to Exist
The prevailing view when Carlsson began was that dopamine was uninteresting — merely a precursor in the manufacturing chain that produces noradrenaline. In 1957 he demonstrated that this was wrong. Dopamine was itself a neurotransmitter in the brain, a signalling molecule in its own right.
The evidence came in two parts. First, he developed methods to measure dopamine concentrations in brain tissue, and showed that dopamine was concentrated in different areas of the brain than noradrenaline — a distribution that made no sense if it were only an intermediate product. It was most heavily concentrated in the basal ganglia, the structures that govern movement. Second came the reserpine experiment: depleting dopamine impaired motor function in animals, and L-dopa treatment reversed the impairment.
The clinical implication was immediate and enormous. If Parkinson's disease involves abnormally low dopamine in the basal ganglia, then supplying L-dopa should relieve it. It did. L-dopa became, and remains, the standard treatment — an unusually direct line from a basic-science measurement to a therapy that has given millions of people back the ability to walk.
Twenty questions, eight minutes on the clock, and a percentile measured against everyone who has taken it. No sign-up.
Take the IQ test →Antipsychotics and Antidepressants
Carlsson did not stop with movement. He went on to elucidate how antipsychotic drugs work — by blocking dopamine receptors — which supplied the mechanistic foundation for understanding a class of medicines that had been discovered empirically and used without anyone knowing quite why they worked.
He then moved to a different transmitter system entirely. Collaborating with the Swedish pharmaceutical company Astra AB during the 1970s and 1980s, he helped derive zimelidine, the first selective serotonin reuptake inhibitor to reach the market. Zimelidine was withdrawn because of rare side effects, but the pathway it opened led to fluoxetine — Prozac — and to the entire SSRI class that reshaped the treatment of depression.
That is an extraordinary range for one career: the dopamine system and the serotonin system, the neurology of movement and the pharmacology of mood, the mechanism of antipsychotics and the origin of modern antidepressants.
Gothenburg and the Principle Underneath
Carlsson spent his later career as professor at the Sahlgrenska Academy of the University of Gothenburg, and it was there in 1963 that he established how antipsychotic medications reduce dopamine's influence on the brain. His long partnership with Astra Hässle — later AstraZeneca — was unusually productive for an academic pharmacologist, contributing to a list of medicines that reaches well beyond neurology: Prozac, but also Seloken, Zelmid, Plendil, and Losec.
The larger claim his work established was not about any single molecule. It was that brain function can be deliberately modified by pharmaceutical intervention targeting neurotransmitters — the principle on which essentially all modern neurological and psychiatric treatment rests. Carlsson's own summary of what he had found was characteristically direct: dopamine, he said, "is involved in everything that happens in our brain, all the important functions."
Why Arvid Is Called a Genius
The specific quality here is experimental clarity — the ability to design a demonstration so decisive that the argument ends. Carlsson's reserpine and L-dopa work is a textbook example of the form: deplete the substance, observe the deficit, restore the substance, observe the recovery. Nothing about it is technically baroque. Its power is in the framing, in knowing exactly which question to put to the animal.
Behind that sits the harder achievement, which was seeing past a consensus. Dopamine was catalogued as a precursor, a step in a pathway, of no independent interest. Carlsson looked at where it accumulated, noticed the distribution was wrong for a mere intermediate, and pursued the anomaly instead of filing it. That is a recognisable cognitive signature: taking seriously the detail that does not fit.
The counter-case is worth stating. Carlsson was not a theorist and left behind no general framework — his contribution is a set of findings, however consequential, rather than a new way of thinking. Much of the work was collaborative, embedded in a field where many groups were converging on brain chemistry at once, and the 2000 Nobel Prize was shared with Paul Greengard and Eric Kandel for related but independent work on signal transduction. The L-dopa therapy, for all its impact, treats symptoms and does not halt the underlying disease. And in later life he took positions outside his expertise, opposing water fluoridation in Sweden, a reminder that eminence in one domain confers nothing in another.
The honest summary is that his genius was that of the great experimentalist rather than the great synthesiser: he asked nature a small number of extremely well-chosen questions and got answers that changed medicine.
Legacy
Carlsson shared the 2000 Nobel Prize in Physiology or Medicine with Greengard and Kandel for discoveries concerning signal transduction in the nervous system. He had already collected the Wolf Prize in Medicine in 1979, the Japan Prize in 1994, and the Feltrinelli Prize in 1999.
He kept working into his nineties, collaborating with his daughter Lena on OSU6162, a dopamine stabiliser — still pursuing, seven decades on, the molecule he had rescued from obscurity. He died in 2018. The measure of what he did is visible in any neurology clinic: dopamine is now a household word, Parkinson's disease has a treatment, and depression has a pharmacology, and all three of those facts trace back to a man in Sweden who declined to accept that a molecule was merely a step on the way to something else.